%20complex.png)
deferasirox
Sign in to saveDeferasirox, sold under the brand name Exjade among others, is an oral iron chelator. Its main use is to reduce chronic iron overload in patients who are receiving long-term blood transfusions for conditions such as beta-thalassemia and other chronic anemias. It is the first oral medication approved in the United States for this purpose.
Key facts
- Drug.Verifiedfields
- changed
- Drug.Watchedfields
- changed
- Drug.verifiedrevid
- 460774502
- Drug.image
- Deferasirox.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 180
- Drug.image2
- Deferasirox ball-and-stick model.png
- Drug.image_class2
- bg-transparent
- Drug.pronounce
- de FER a sir ox
- Drug.tradename
- Exjade, others
- Drug.MedlinePlus
- a606002
- Drug.DailyMedID
- Deferasirox
- Drug.pregnancy_AU
- C
- Drug.routes_of_administration
- By mouth
- Drug.ATC_prefix
- V03
- Drug.ATC_suffix
- AC03
- Drug.legal_AU
- S4
- Drug.legal_UK
- POM
via Wikipedia infobox
Research
1,446 papers- Deferasirox alleviates DSS-induced ulcerative colitis in mice by inhibiting ferroptosis and improving intestinal microbiota.Life sciences · 2023
- Deferasirox.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2007
- Deferasirox-associated Fanconi syndrome in adult patients with transfusional iron overload.Vox sanguinis · 2021
- Deferasirox nephrotoxicity-the knowns and unknowns.Nature reviews. Nephrology · 2014
- Deferasirox: pharmacokinetics and clinical experience.Expert opinion on drug metabolism & toxicology · 2012
via PubMed
Article
4 sectionsContents
- Properties
- Synthesis
- Risks
- References
Deferasirox, sold under the brand name Exjade among others, is an oral iron chelator. Its main use is to reduce chronic iron overload in patients who are receiving long-term blood transfusions for conditions such as beta-thalassemia and other chronic anemias. It is the first oral medication approved in the United States for this purpose.
It was approved by the US Food and Drug Administration (FDA) in November 2005. According to the FDA (May 2007), kidney failure and cytopenias have been reported in patients receiving deferasirox tablets for oral suspension. It is approved in the European Union by the European Medicines Agency (EMA) for children six years and older for chronic iron overload from repeated blood transfusions. It is on the World Health Organization's List of Essential Medicines.
Gallery (2)
Connections
Categories
2-Hydroxyphenyl compoundsAntidotesBenzoic acidsChelating agentsChelating agents used as drugsDrugboxes which contain changes to verified fieldsDrugboxes which contain changes to watched fieldsDrugs developed by NovartisDrugs with non-standard legal statusECHA InfoCard ID from WikidataOrphan drugsTriazoles